Aemetis (NASDAQ:AMTX) Raised to Sell at StockNews.com

StockNews.com upgraded shares of Aemetis (NASDAQ:AMTX) to a sell rating in a research report sent to investors on Wednesday.

A number of other equities research analysts have also issued reports on the stock. Truist Financial reaffirmed a hold rating and set a $4.00 price objective (up from $3.50) on shares of Aemetis in a report on Monday, May 13th. HC Wainwright reaffirmed a buy rating and set a $28.00 price objective on shares of Aemetis in a report on Friday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Hold and a consensus price target of $12.13.

Aemetis Trading Down 6.4 %

Aemetis stock opened at $2.49 on Wednesday. The firm has a 50 day moving average of $3.26 and a 200 day moving average of $3.69. The firm has a market capitalization of $110.55 million, a price-to-earnings ratio of -2.13 and a beta of 1.32. Aemetis has a 12-month low of $2.29 and a 12-month high of $7.82.

Aemetis (NASDAQ:AMTX) last released its earnings results on Thursday, August 1st. The specialty chemicals company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The company had revenue of $66.56 million for the quarter, compared to the consensus estimate of $75.37 million. During the same period last year, the company earned ($0.68) earnings per share. On average, analysts predict that Aemetis will post -1.59 EPS for the current year.

Insider Activity

In related news, Director John R. Block sold 51,580 shares of the firm’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $3.49, for a total value of $180,014.20. Following the completion of the sale, the director now directly owns 14,001 shares in the company, valued at $48,863.49. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 14.34% of the company’s stock.

Institutional Trading of Aemetis

Institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in shares of Aemetis during the first quarter worth $60,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Aemetis during the first quarter worth $84,000. Rhumbline Advisers lifted its position in shares of Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after purchasing an additional 50,528 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Aemetis during the second quarter worth $306,000. 27.02% of the stock is currently owned by institutional investors.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.